Key Takeaways
- • WindRose Health Investors has recapitalized Verified Clinical Trials, a global research-subject registry that prevents duplicate enrollment and protocol violations in clinical trials, with no transaction value disclosed.
- • Verified Clinical Trials, founded 16 years ago by Mitchell Efros and Kerri Weingard, will transition to new CEO Howard Miller while founders remain active in the business.
- • WindRose, a New York-based healthcare-services investor managing approximately $8 billion in assets, targets profitable healthcare companies and views the investment as reducing downstream risk across clinical research constituents.
- • The transaction was advised by Cantor Fitzgerald & Co. (company counsel) and McDermott Will & Schulte (legal), with Latham & Watkins advising WindRose on the recapitalization.
- • Verified Clinical Trials' database serves research sites, sponsors, and contract research organizations, addressing patient safety and data integrity—critical compliance issues in regulated clinical research.
Summary
WindRose Health Investors has recapitalized Verified Clinical Trials, strengthening the clinical-research infrastructure company's capital position and management depth. Verified Clinical Trials operates a global registry designed to identify and prevent duplicate subject enrollment and protocol violations—a mission-critical function in the heavily regulated clinical trials ecosystem. The database is utilized by research sites, trial sponsors, and contract research organizations to maintain patient safety standards and ensure data integrity across multisite studies.
Founded 16 years ago, Verified Clinical Trials was established by Mitchell Efros and Kerri Weingard, who remain engaged in the business following the recapitalization. Howard Miller assumes the role of chief executive officer, bringing fresh leadership while the founders maintain active involvement. This leadership transition, paired with WindRose's capital infusion, positions the company for operational scaling and potential expansion of its service offerings to the clinical research community.
WindRose Health Investors, headquartered in New York, manages approximately $8 billion in assets and focuses exclusively on profitable healthcare-services companies. The recapitalization aligns with WindRose's investment thesis that infrastructure plays reducing operational and regulatory risk across healthcare value chains command durable margins and repeat-customer relationships. CJ Burnes, a WindRose partner, characterized Verified Clinical Trials as a platform that "proactively reduces downstream risk for all clinical research constituents," reflecting the investor's view that the company addresses a structural pain point shared across sponsors, contract research organizations, and research sites managing complex, multi-site protocols.
Financial advisors on the transaction included Cantor Fitzgerald & Co., which provided company counsel, and McDermott Will & Schulte, which handled legal matters. Latham & Watkins served as legal counsel to WindRose on the transaction structuring and negotiation.
Founded 16 years ago, Verified Clinical Trials was established by Mitchell Efros and Kerri Weingard, who remain engaged in the business following the recapitalization. Howard Miller assumes the role of chief executive officer, bringing fresh leadership while the founders maintain active involvement. This leadership transition, paired with WindRose's capital infusion, positions the company for operational scaling and potential expansion of its service offerings to the clinical research community.
WindRose Health Investors, headquartered in New York, manages approximately $8 billion in assets and focuses exclusively on profitable healthcare-services companies. The recapitalization aligns with WindRose's investment thesis that infrastructure plays reducing operational and regulatory risk across healthcare value chains command durable margins and repeat-customer relationships. CJ Burnes, a WindRose partner, characterized Verified Clinical Trials as a platform that "proactively reduces downstream risk for all clinical research constituents," reflecting the investor's view that the company addresses a structural pain point shared across sponsors, contract research organizations, and research sites managing complex, multi-site protocols.
Financial advisors on the transaction included Cantor Fitzgerald & Co., which provided company counsel, and McDermott Will & Schulte, which handled legal matters. Latham & Watkins served as legal counsel to WindRose on the transaction structuring and negotiation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.